Retevmo

Risk of serious hepatotoxicity. Monitor ALT/AST prior to initiation, every 2 weeks during 1^st 3 months, then monthly thereafter and as clinically indicated. Risk of severe interstitial lung disease (ILD)/pneumonitis. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Withhold and promptly evaluate for ILD if acute or worsening of respiratory symptoms occur. Uncontrolled hypertension: do not initiate. Optimize BP prior to initiation, monitor after 1 week, then at least monthly thereafter and as clinically indicated. Monitor patients with significant risk of QTc prolongation (including known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled HF). Assess QT interval, electrolytes, TSH at baseline and periodically during treatment. Correct hypokalemia, hypomagnesemia, and hypocalcemia prior to initiation and during therapy. Withhold if hypersensitivity occurs and begin corticosteroids. Permanently discontinue if recurrent hypersensitivity, severe or life-threatening hemorrhage occurs. Tumor lysis syndrome: monitor in those with rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration. Impaired wound healing: withhold for ≥7 days prior to elective surgery; do not give for ≥2 weeks after major surgery and until adequate healing. Monitor thyroid function before and periodically during treatment; treat as clinically indicated. Clinically significant active cardiovascular disease, recent MI: not studied. ESRD. Severe hepatic impairment (total bilirubin >3–10×ULN and any AST): reduce dose (see Adults). Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective contraception during and for 1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Risk of serious hepatotoxicity. Monitor ALT/AST prior to initiation, every 2 weeks during 1^st 3 months, then monthly thereafter and as clinically indicated. Risk of severe interstitial lung disease (ILD)/pneumonitis. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Withhold and promptly evaluate for ILD if acute or worsening of respiratory symptoms occur. Uncontrolled hypertension: do not initiate. Optimize BP prior to initiation, monitor after 1 week, then at least monthly thereafter and as clinically indicated. Monitor patients with significant risk of QTc prolongation (including known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled HF). Assess QT interval, electrolytes, TSH at baseline and periodically during treatment. Correct hypokalemia, hypomagnesemia, and hypocalcemia prior to initiation and during therapy. Withhold if hypersensitivity occurs and begin corticosteroids. Permanently discontinue if recurrent hypersensitivity, severe or life-threatening hemorrhage occurs. Tumor lysis syndrome: monitor in those with rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration. Impaired wound healing: withhold for ≥7 days prior to elective surgery; do not give for ≥2 weeks after major surgery and until adequate healing. Monitor thyroid function before and periodically during treatment; treat as clinically indicated. Clinically significant active cardiovascular disease, recent MI: not studied. ESRD. Severe hepatic impairment (total bilirubin >3–10×ULN and any AST): reduce dose (see Adults). Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective contraception during and for 1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Risk of serious hepatotoxicity. Monitor ALT/AST prior to initiation, every 2 weeks during 1^st 3 months, then monthly thereafter and as clinically indicated. Risk of severe interstitial lung disease (ILD)/pneumonitis. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Withhold and promptly evaluate for ILD if acute or worsening of respiratory symptoms occur. Uncontrolled hypertension: do not initiate. Optimize BP prior to initiation, monitor after 1 week, then at least monthly thereafter and as clinically indicated. Monitor patients with significant risk of QTc prolongation (including known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled HF). Assess QT interval, electrolytes, TSH at baseline and periodically during treatment. Correct hypokalemia, hypomagnesemia, and hypocalcemia prior to initiation and during therapy. Withhold if hypersensitivity occurs and begin corticosteroids. Permanently discontinue if recurrent hypersensitivity, severe or life-threatening hemorrhage occurs. Tumor lysis syndrome: monitor in those with rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration. Impaired wound healing: withhold for ≥7 days prior to elective surgery; do not give for ≥2 weeks after major surgery and until adequate healing. Monitor thyroid function before and periodically during treatment; treat as clinically indicated. Clinically significant active cardiovascular disease, recent MI: not studied. ESRD. Severe hepatic impairment (total bilirubin >3–10×ULN and any AST): reduce dose (see Adults). Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective contraception during and for 1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).